The Lynx Group

FDA Grants Priority Review for Ruxolitinib for the Treatment of Myelofibrosis

August 2011, Vol 2, No 5

The US Food and Drug Administration (FDA) has granted priority review for the investigational drug ruxolitinib as a potential treatment for patients with myelofibrosis, a blood cancer with few treatment options. There are currently no FDA-approved treatments for this condition. The status of a priority review indicate that the drug either is perceived as offering a major advance in treatment or provides treatment to a condition with no approved therapies.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: